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ABSTRACT (265 words)
PURPOSE: The advanced prostate cancer therapeutic landscape has changed dramatically over
the last several years, resulting in improved overall survival for patients with both castrationnaive and castration-resistant disease. The evolution and development of novel next generation
imaging (NGI) techniques will affect diagnostic and therapeutic decision-making. Clinicians
must navigate when and which NGI techniques to use and how to adjust treatment strategies
based upon their results, oftentimes in the absence of correlative therapeutic data. Therefore,
guidance is needed based on best available information and current clinical experience.
MATERIALS AND METHODS: The RADAR III Group convened to offer guidance on the
use of NGI to stage prostate cancer based on available data and clinical experience. The group
also discussed the potential impact of NGIs on treatment options based on earlier detection of
disease.
RESULTS: The group unanimously agreed that progression to metastatic disease is a seminal
event for patient management. NGI techniques are able to detect previously undetectable
5

metastases, which could redefine the phases of prostate cancer progression. Hence, earlier
treatment, either systemic or locally directed, may positively alter patient outcomes.
CONCLUSIONS: The RADAR III Group recommends NGI techniques for select patients
suspected of disease progression based on laboratory (biomarker) values, comorbidities, and
symptoms. Currently, 18F-fluciclovine and 68Gallium (Ga) PSMA PET/CT are the NGI agents
with a favorable combination of availability, specificity, and sensitivity. There is ongoing
research for additional NGI technologies, which may offer improved diagnostic accuracy and
therapeutic options. As NGI techniques evolve and presumably result in improved global
accessibility, a clinician’s ability to detect micrometastases may be enhanced for both decisionmaking and patient outcomes.

Key Words: Next generation imaging, guidelines, treatment, metastatic prostate cancer.
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MANUSCRIPT (~4235 words—will be less once the references are superscripted)

INTRODUCTION
Prostate cancer is the most frequently diagnosed noncutaneous cancer in men according to the
2018 estimates by the American Cancer Society. (ACS facts and figures 2018) In the United
States (US), approximately 164,690 new cases will be diagnosed, and an estimated 29,430 men
will die from prostate cancer. (ACS facts and figures 2018) Prostate cancer, especially for the
high-risk patient, is a progressive disease (table 1). With ongoing advancements in imaging
technology, the ability to identify previously undetectable metastases may result in a shift in the
definition of disease states and improved outcomes.
Table 1. Phases of Prostate Cancer Disease States
Prostate Cancer Phase

References

Localized prostate cancer

Mena EJNMMI 2017

Biochemically recurrent (BCR)/persistent disease after
local therapy

Mena EJNMMI 2017

Nonmetastatic castration-resistant prostate cancer (M0
CRPC) or nmCRPC

Tombal Ann Oncol 2012

Metastatic hormone-sensitive prostate cancer (M1
HSPC)

Hoimes TAMO 2010

Metastatic castration-resistant prostate cancer
(MCRPC)

Hoimes TAMO 2010

Treatment-emergent neuroendocrine prostate cancer

Epstein Am J Surg Pathol 2014

Anantharaman ERAT 2017

7

Treatment options and regimens for patients with advanced prostate cancer, both hormone naive
and castration resistant, have increased in recent years and now include novel androgen axis
inhibitors, immunotherapy, targeted alpha particle therapy, and chemotherapy. (Lindenberg
JAMA Oncology 2017) Six treatments for metastatic CRPC (mCRPC) and nonmetastatic CRPC
(nmCRPC), all with different mechanisms of action and overall survival (OS) benefit, have been
approved since 2010 (i.e., sipuleucel-T, cabazitaxel, abiraterone acetate plus prednisone,
enzalutamide, radium-223, apalutamide). (Crawford Urology 2015; Smith N Engl J Med 2018)
Additional therapies are being studied, such as poly-(adenosine diphosphate-ribose) polymerase
(PARP) and PI3K/AKT pathway inhibitors. Studies suggest that earlier detection of advanced
disease in specific patient populations, coupled with these newer treatment options, will
potentially increase the OS benefit for these patients, especially in correlation with improved
predictive markers to help guide treatment selection. (Schellhammer Urology 2013; Ost JCO
2017)
The development of metastases is a seminal event during prostate cancer progression, as the
development of CRPC heralds a potentially fatal disease. Although OS has improved from
approximately 18 months to 3 years since approval of new therapeutic agents, CRPC is
invariably fatal. There are risk factors that are prognostic of worse outcomes. In a retrospective
study of 205 patients with mCRPC, advanced age, time since diagnosis, greater number of bone
metastases, higher prostate-specific antigen (PSA) levels, and shorter PSA doubling time
(PSADT) were all associated with shorter OS time. (Moreira CGC 2017)

8

REVIEW OF PRIOR RADAR GROUP RECOMMENDATIONS
The RADAR I Group initially convened to provide recommendations for the early identification
of prostate cancer metastases. RADAR I recommended preferred traditional imaging modalities,
and specifically when and how often the imaging should be performed (figure 1). (Crawford
Urology 2014)
Figure 1. RADAR I Recommendations

Reprinted with permission from Crawford 2014.
Subsequently, the RADAR II Group met to elaborate on the work of the original RADAR I
Group and provided recommendations on the therapeutic sequencing, combining, or layering of
approved treatments for patients with metastatic prostate cancer who developed CRPC.
(Crawford Urology 2017)
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METHODS
The RADAR III Group convened to evaluate the use of next generation imaging (NGI)
modalities and reviewed the rationale for obtaining specific scans, the frequency of imaging,
interpreting imaging results and their subsequent clinical utility, and finally, proposing a clinical
decision-making treatment algorithm. RADAR III discussed both accessibility and utilization
amongst medical oncologists, radiation oncologists, and urologic oncologists within various
practice settings (eg, academic vs community; rural vs urban). Recommendations were made
regarding prostate cancer nomenclature in order to accurately represent the changing landscape
of imaging and subsequent treatment decision-making. RADAR III acknowledges the limitations
of making recommendations when level one evidence-based data are not yet available. However,
given the rapid development and increased availability of these newer imaging modalities, and as
practitioners are faced with making clinical decisions, recommendations are needed. RADAR III,
based on their expert opinion and clinical experience, herein provide guidance for the utilization
of these NGIs.
Updates were made to the original RADAR I guidelines to include recommendations on
emerging NGI technologies, based on specificity and sensitivity of published reports and realworld availability. RADAR III also acknowledged the importance of incorporating NGI into
future clinical trial designs. Importantly, it was agreed that earlier initiation of treatment may
lead to better outcomes with optimal patient selection. More definitive clinical trials are required
to determine the optimal utilization of NGI technologies.
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NEXT GENERATION IMAGING MODALITIES
Novel Positron Emission Tomography (PET) Radiotracers
PET is a functional imaging technique that is able to detect metabolic activity, blood flow,
apoptosis, etc. (Evans PRO 2017)
The use of PET/CT in patients with prostate cancer has been advanced by the development of
new radiotracers, including 18F-fluciclovine, 11C-choline, agents targeting prostate-specific
membrane antigen (PSMA), 16beta-18F-fluoro-5alpha-dihydrotestosterone (18F-FDHT), and 11C
acetate. (Fischer EJNMMI 2016) (Lindenberg JAMA Oncology 2017)
These NGI PET/CT radiotracers allow for the detection of previously undetectable metastases by
traditional imaging studies (CT and technetium-99m bone scans) due to improved sensitivity and
specificity. Several of these NGI techniques have been approved by the Food and Drug
Administration (FDA) for use in patients with prostate cancer. These include 18F-fluciclovine
(18F-FACBC), 11C choline, sodium fluoride (18F-NaF), and fluorodeoxyglucose 18F-(FDG). FDA
approval generally signifies that the scans can be performed reproducibly and safely.
Additionally, the FDA—as well as reimbursement agencies—generally require a demonstration
of clinical utility via alterations in treatment decisions based on the use of the specific imaging
modality. (Evans 2018; FDA Press Release) However, FDA approval for these scans does not
necessarily mean that proven value in clinical practice has been established; specifically, it does
not mandate that treatment decisions are altered in a fashion that leads to clinical benefit for a
patient, either through efficacy, safety, or quality of life. In fact, there is currently very little
clinical data demonstrating that the use of NGI improves outcomes. Moreover, FDA approval
does not guarantee reimbursement by Medicare or third-party payers.
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Table 2. Next Generation Imaging (Lindenberg JAMA Oncol 2017, Bach-Gansmo J Urol 2017)

Modified with permission from Lindenberg 2017.
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NGI TRACERS
18F-fluciclovine
18

PET/CT (18F-FACBC, Axumin®)

F-fluciclovine is a synthetic L-leucine analog that exhibits high tumor-specific accumulation in

both primary and metastatic prostate carcinomas through targeting amino acid transports, which
are upregulated in prostate cancer. (Okudair JNM 2011, Schuster JNM 2007) It was recently
approved by the FDA for patients with suspected recurrence based on elevated PSA following
prior treatment. (Axumin PI 2016)
18

F-fluciclovine demonstrated superiority when compared with other NGIs, such as 18F-choline

and 11C-choline. A meta-analysis of different PET tracers demonstrated that 18F-fluciclovine had
greater ability to detect locally recurrent disease versus 18F-choline, although the difference was
not statistically significant. (Yu AJNMMI 2014) In a prospective study of 89 patients comparing
the accuracy of 18F-FACBC and 11C-choline PET/CT in patients undergoing prostatectomy who
presented with biochemical relapse, 18F-FACBC demonstrated detection superiority over 11Ccholine. Categorizing patients by PSA level, the percent of patients with true-positive findings
were generally higher with 18F-FACBC than with 11C-choline (table 2). (Nanni Eur J Nucl Med
Mol Imaging 2016)
Limitations of 18F-fluciclovine include potential long-term risk of secondary cancers, unknown
responsiveness to ADT, limited information regarding imaging in the CRPC setting, and overall
limitations of potential variability in sensitivity and specificity as it relates to location of
metastases (eg, PSA, PSADT). (Bach-Gansmo J Urol 2017)
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11C-choline

PET/CT

11

C-choline has variable sensitivity and specificity for biochemical recurrence, especially at low

PSA levels. (Nanni Eur J Nucl Med Mol Imaging 2016) 11C-choline has limited availability due
to its very short half-life of 20.4 minutes, which requires an on-site cyclotron that few centers in
the US possess. (Czernin PET Clin 2009)
18F-sodium

18

fluoride (18F NaF) PET/CT

F-NaF is a radioactive tracer that diffuses into the bone, leading to an exchange of fluoride ions

with hydroxide ions of the hydroxyapatite crystals, eventually forming fluorapatite. (Kurdziel J
Nucl Med 2012) 18F-NaF PET/CT has higher specificity and sensitivity than traditional bone
scans or planar single-photon emission CT imaging. (Harmon JCO 2017) Despite this, the
Centers for Medicare and Medicaid Services (CMS) is no longer reimbursing 18F-NaF for
prostate cancer management.
PSMA Ligands
Novel imaging modalities using radiolabeled tracers with PSMA, such as 68Gallium (Ga) PSMA
PET/CT, have shown promising results with best utilization in biochemical recurrence. (Perera
2016; Udovicich 2017) Review of the literature generally favors PSMA-based agents versus
choline and fluciclovine for detection of recurrence as a function of low PSA levels; however,
comparison studies have not been performed (table 3). (Evans 2018) Based on the growing body
of literature regarding its clinical utility, the availability of PSMA within the US is limited but
beginning to increase. (Evans 2018)
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Table 3. Summary of Data Evaluating Prostate Cancer PET Detection Rates as a Function
of PSA (Evans 2018)

Reprinted with permission from Evans 2018.

68Gallium

(Ga)-PSMA PET/CT

Rapidly developed and implemented in different centers and clinics in Europe, Australia, South
America, and the US, gallium citrate (68 Ga)-PSMA-HBED-CC is one of the more utilized
ligands in this class of small molecule inhibitors worldwide and has high sensitivity (63%-86%)
and specificity (95%-100%) even at low PSA levels based on different single- and multiinstitutional trials. (Öbek EJNMMI 2017; Maurer J Urol 2016; Kranzbühler EJNMMI 2017)
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In a systematic review and meta-analysis of reported predictors of positive 68Ga-PSMA PET and
corresponding sensitivity and specificity profiles, 16 articles involving 1309 patients were
analyzed. The overall percentage of positive 68Ga-PSMA PET among patients was 40% (95%
confidence interval [CI] 19%-64%) for primary staging and 76% (95% CI 66%-85%) for BCR.
Positive 68Ga-PSMA PET scans for BCR patients increased with pre-PET PSA. For the PSA
categories 0–0.2, 0.2–1, 1–2, and >2 ng/ml, 42%, 58%, 76%, and 95% scans, respectively, were
positive. Shorter PSADT increased 68Ga-PSMA PET positivity. The summary sensitivity and
specificity were both 86% on per-patient analysis, and the summary sensitivity and specificity
were 80% and 97%, respectively, on pre-lesion analysis. (Perera 2016)
A prospective survey of referring physicians showed that PSMA-11 PET/CT results in actually
implemented management changes in more than 50% of prostate cancer patients with BCR
(54/101; 53%). (Calais 2017)
In a study of 68Ga-PSMA in 70 patients with biochemical recurrence after radical prostatectomy
with extended lymph node dissection, the sites of recurrent disease included the prostatic fossa
(27%), pelvic lymph nodes (14.3%), both the fossa and pelvic lymph nodes (4.3%), and outside
the pelvis (8.6%). (van Leeuwen BJUI 2016a) These results show that 68Ga-PSMA is able to
detect local, regional, and distant metastatic disease even in patients with low PSA levels. The
investigational nature of 68Ga-PSMA, as well as the requirement for a gallium 68 generator
limits its current availability in the US.
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N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine (18F-DCFBC)
PET/CT
18

F-DCFBC is a small molecule PSMA inhibitor useful for detecting high-grade (Gleason 8 and

9) and larger sized (≥1.1 ml) primary tumors reliably. (Rowe JNM 2015) It displays little uptake
in benign prostatic hyperplasia and, therefore, may be useful in differentiating malignant from
nonmalignant prostate tissues.
18F-DCFPyL

PSMA PET/CT

18

F-DCFPyL is a second-generation 18F-labeled PSMA agent. In a small comparative study with

68

Ga-PSMA in 14 patients with BCR disease, the 18F-DCFPyL scan was slightly more sensitive

with higher tumor-to-background ratios than 68Ga-PSMA. (Dietlein Mol Imag Bio 2015) In that
study, 18F-DCFPyL detected all the suspicious lesions detected by 68Ga-PSMA plus additional
suspicious lesions in 3/14 patients, indicating a high sensitivity for 18F-DCFPyL.
18F-FDHT

PET/CT

The androgen receptor is overexpressed in the majority of patients with CRPC. 18F-FDHT, which
is chemically similar to dihydrotestosterone, is a ligand for the androgen receptor. (Bednarova
TAU 2017) In a clinical trial of patients with advanced aggressive prostate cancer, 18F-FDHT
showed lower sensitivity for prostate cancer detection compared to 18F-FDG (86% versus 97%,
respectively). For in vivo estimation of the androgen receptor expression in patients on ADT,
however, 18F-FDHT may be the better PET tracer for the assessment of treatment response.
(Larson J Nucl Med 2004) Overall, there are very limited clinical data to date on 18F-FDHT.
(Bednarova TAU 2017) This radiotracer has demonstrated utility in assessing androgen receptor
blockade with second-line antiandrogens. (Lindenberg Curr Urol Rep 2016; Talbot Q J Nucl
Med Mol Imaging 2015)
17

11C-acetate

PET/CT

In a pooled meta-analysis of 23 studies investigating 11C-acetate PET, this radiotracer had a
suboptimal sensitivity of 75.1% at detecting primary tumors, although it did have a high
specificity of 93% in identifying the location of relapse. (Mohsen BJUI 2013) Taking into
account the complexity of imaging with this tracer and the short half-life of 11C (20.4 minutes)
requiring on-site synthesis, the availability of 11C-acetate PET for imaging in prostate cancer is
very limited. (Mohsen BJUI 2013) The isotope’s short half-life requires an on-site cyclotron, and
there are only a few centers in the US that have this access.
Medicare Coverage
Only a few NGI PET/CT scans are currently covered by Medicare (table 4). As of early 2018,
the CMS has withdrawn the National Oncology PET Registry (NOPR) program for 18NaF
PET/CT. The NOPR program was a collaboration of the American College of Radiology
Imaging Network (ACRIN), the American College of Radiology (ACR), and the Academy of
Molecular Imaging (AMI), to ensure access to Medicare reimbursement for certain types of PET.
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Table 4. Medicare Coverage for Several NGI Techniques

Whole-body MRI has been used successfully in Europe and has shown good sensitivity and
specificity in bone metastases. In the US, there are no established current procedural terminology
(CPT) codes for reimbursement for whole body MRI. (Wibmer 2015)

DISCUSSION
POTENTIAL CLINICAL IMPACT OF NGI
Disease evaluation following unsuccessful initial interventional therapy is critical as salvage
therapies may be curative but may also be associated with morbidity and not beneficial if distant
disease exists. Local recurrence of prostate cancer can be detected by multiparametric MRI with
components such as anatomical T2 weighting and functional imaging (e.g., diffusion weighted
19

imaging, dynamic contrast-enhanced imaging). (Lindenberg JAMA Oncol 2017) However, both
local recurrences and distant metastases can be better confirmed with NGI. (Evans 2018)
NGI techniques are able to identify previously undetectable prostate cancer metastases, allowing
for consideration of earlier treatment that has the potential to affect long-term outcomes. There
has been a body of evidence that suggests that earlier therapeutic intervention leads to better
outcomes for patients with advanced prostate cancer in both the hormone-sensitive and
castration-resistant settings. This has been demonstrated for chemotherapy (CHAARTED),
immunotherapy (IMPACT/quartiles data), and novel androgen receptor-targeted agents
(LATITUDE/STAMPEDE). (NCCN PC 2018; Sweeney NEJM 2015; Schellhamer Urology
2013; Fizazi NEJM 2017; James NEJM 2017; Ost JCO 2017) However, the use of NGI has the
potential to enhance outcomes as it can allow for earlier therapy in a patient with a very low
PSA, when theoretical cure or significant tumor reduction may lead to benefits. In 2018, this
notion is still hypothesis-generating, and thus requires prospective trials in order to evaluate the
efficacy and risks of such earlier interventions. However, a recently published phase 2 study in
patients with oligo-recurrent prostate cancer does suggest benefit of early intervention. (Ost JCO
2017)
The availability of NGI has the potential to redefine the traditionally accepted stages in prostate
cancer progression. Many patients diagnosed as M0 hormone sensitive (m0 HS) and M0
castration-resistant prostate cancer (m0 CRPC) based on traditional scans, would now be
potentially upgraded as M1 HS and M1 CRPC using the improved NGI techniques. (Lei 2016;
Botrel 2016; Gundem 2015) PROSPER and SPARTAN trials now support the use of
enzalutamide and apalutamide in men with M0 CRPC (also identified as nmCRPC). These
studies have utilized traditional imaging studies to determine the M0 disease state, nmCRPC, and
20

to ascertain progression. It is the opinion of RADAR III that NGI should be evaluated and could
find utility for both M0 disease states.

NGI RECOMMENDATIONS BY THE RADAR III GROUP
The transition to advanced prostate cancer is of crucial clinical importance and NGI techniques
allow for the early identification of previously undetectable prostate cancer metastases. No single
NGI imaging scan can detect all metastases required for clinical decision-making. Of all the NGI
tests considered, the 18F-fluciclovine PET scan has the best combination of availability,
specificity, and sensitivity in the US. PSMA PET/CT scans show great diagnostic potential, but
likely won’t be available for widespread use in the US for several years, although it is being
regularly used in some other nations (eg, Australia, New Zealand, Germany, and Brazil). It also
may be ideal to couple with the development of novel therapeutic radiopharmaceuticals targeted
to PSMA. In general, RADAR III recommends the use of available NGI techniques, but the use
of these scans varies based on each stage of advanced disease, as outlined in figure 2.
The RADAR III group recommends FDA-approved systemic therapy (sipuleucel-T, cabazitaxel,
abiraterone acetate plus prednisone, enzalutamide, radium-223) for patients with confirmed M1
CRPC who are clinically deemed fit enough to undergo such treatment. (Crawford Urology
2015) These treatments, which have been proven to extend OS in men with mCRPC, require
confirmation of metastatic disease on scan before being initiated.
In early 2018, the FDA approved apalutamide, a next-generation androgen receptor inhibitor, for
patients with M0 CRPC. A phase 3 SPARTAN trial of 1207 men with nonmetastatic CRPC and
PSADT of 10 months or less demonstrated that median metastasis-free survival was 40.5 months
21

with apalutamide compared with 16.2 months with placebo (p<0.001). Time to symptomatic
progression was also significantly longer with apalutamide than with placebo. (Smith N Engl J
Med 2018)
There are also promising new treatments under development for patients with M0 CRPC,
including earlier use of enzalutamide based on the positive PROSPER trial, for which an
expanded approval is currently being sought. Another agent, darolutamide, has potential to help
delay the progression to metastatic disease. It will be important to consider the inclusion of NGI
techniques in clinical trials involving these agents in the M0 setting.

22

Figure 2. RADAR III Recommendations on NGI (Crawford 2014)

Top portion of figure adapted from Crawford 2014.

Newly Diagnosed Patients
In newly diagnosed patients with suspected localized prostate cancer, RADAR I recommended
the use of traditional CT/bone scans for men who had at least 2 of the 3 following criteria:
•

PSA level >10 ng/ml

•

Gleason score ≥7

•

Palpable disease (≥T2b)

RADAR III recommends utilization of traditional scans with consideration for NGI only if the
traditional scans are equivocal or negative and the clinician still suspects disease progression
23

based on various factors, including—but not limited to—the following criteria: (NCCN
V1.2018)
•

Gleason score

•

PSA levels

•

PSA velocity in untreated patients

•

Patients meeting NCCN very high risk or locally advanced/N1 disease should be
considered for NGI at initial diagnosis

As an example, consider a healthy 63-year-old male with PSA of 60 ng/ml, Gleason score of 7 in
10/12 cores, and negative technetium-99m bone scan and pelvic CT scan. We would recommend
an NGI evaluation.
Although there is currently a lack of level one evidence to support the use of NGI, there are
emerging clinical data to support this approach. A recently published prospective phase 2
PMSA-targeted PET/CT study was able to detect prostate cancer metastases in patients thought
to have clinically localized disease based on traditional imaging, and thereby proceeded with
interventional therapy. (Gorin J Urol 2018)

Biochemical Recurrent Patients
In BCR patients who have been definitively treated, RADAR III suggests that NGI may be
considered for patients with PSA ≥0.5 ng/ml after treatment. Patients with PSA <0.5 ng/ml can
be considered based on specific performance of various NGI techniques. NGI should only be
performed if the patient is willing to undergo metastasis-directed therapy (MDT) in the event of
a positive scan, or they are seeking a rationale to initiate systemic therapy. If a scan is not
performed, PSA should be monitored closely and NGI be reconsidered if the PSA rises.
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M0 Castration-Resistant Patients
For patients with M0 CRPC, RADAR I recommended that a CT/bone scan should be performed
when PSA ≥2 ng/ml. If negative, subsequent scans should be performed when PSA = 5 ng/ml
and every doubling of PSA levels thereafter (based on PSA testing every 3 months).
RADAR III reviewed NGI for M0 CRPC. NGI could identify metastases earlier, which would
allow for patients to receive treatment with the 5 agents that have regulatory approval in the M1
CRPC setting. Although earlier intervention using this approach has not been validated through
prospective clinical trials, there is evidence to support the concept that intervening earlier with
systemic therapies for M1 CRPC (sipuleucel-T) and for M0 CRPC (apalutamide), when disease
burden is lower, may have a positive impact for some patients.
RADAR III suggests follow-up imaging every 6-12 months or more frequently based on PSADT
<6 months, and/or symptoms in patients undergoing therapy for M0 CRPC. If traditional
imaging fails to detect metastatic disease, NGI can be performed only if approved therapies in
the M1 space are being considered. RADAR III cautions against ceasing therapy for PSA rise
alone.
Given the recent approval of apalutamide for M0, the value of NGI in this setting has yet to be
determined. As such, NGI should only be considered when a patient progresses and M1
treatments are being considered.
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Patients With M1 Prostate Cancer Undergoing Treatment
RADAR III expanded the original RADAR I recommendations to include additional guidance on
imaging techniques for M1 patients. The expanded recommendations include imaging using
traditional scans and moving on to NGI only if the traditional scans are negative and the clinician
still suspects disease progression based on at least one of the following:
•

With every doubling of PSA since the previous image was taken

•

Every 6-9 months in the absence of PSA rise

•

Change in symptomatology

•

Change in performance status

The goal of scanning in the M1 setting is to confirm disease progression to inform clinical
decision-making. If disease progression is confirmed on scan, RADAR III recommends the
consideration of the use of therapeutic layering. Therapeutic layering is different from
combination therapy, in which 2 or more therapies are initiated simultaneously. Therapeutic
layering, as defined by the RADAR II Group, represents a clinical point where one or more
agent(s) are added onto an existing therapy. In CRPC, all treatment interventions are technically
layering of therapy since agents are added to the foundation of ADT. To see specific
recommendations on therapeutic layering for M1 CRPC patients, please refer to the RADAR II
manuscript. (Crawford 2017)
The use of NGI regarding treatment response has yet to be definitively established. Limitations
include comparison of NGI and non-NGI techniques, as well as the significance of
semiquantitative analysis of NGI.
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CONSIDERATIONS FOR CHANGE IN NOMENCLATURE
Prostate cancer’s heterogeneous nature requires better terminology that more clearly defines its
response to specific therapies. As the disease has continued to evolve biologically over the years
in a much different way, our recommendation is to re-name CRPC as endocrine-resistant prostate
cancer (ERPC).
Clinicians created an iatrogenic disease state by treating men with ADT who have a rising PSA
after a local treatment. Once men exhibit progression after ADT, they have developed endocrine
resistance and if no metastasis are detected, they have been categorized as M0 or nmCRPC. The
original intent of the term CRPC described metastatic disease while failing ADT. Consequently,
the M0 CRPC was added to categorize these men. Two major advances have occurred that
suggest a need to redefine this entire disease state. The first is NGI, which offers an opportunity
to more accurately assess disease progression, and secondly, 2 trials have demonstrated a
significant benefit to newer third generation antiandrogen in the nonmetastatic endocrineresistant state. RADAR III believes these events dictate the need for reassessment and
development of renewed nomenclature and guidelines.
Our recommendations are to now name these states as ERPC instead of CRPC. The rationale for
this terminology was suggested several years ago. (Crawford & Petrylak JCO 2010). The
RADAR III guidelines for this ERPC space include:
1. Men experiencing PSA or other signs of progression after adequate ADT for any stage of
prostate cancer be labeled as ERPC
2. Men who experience progression after adequate ADT for biochemical progression and
negative conventional imaging be labeled nmERPC (nonmetastatic conventional
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imaging), nmERPC* (nonmetastatic *NGI performed and since nmERPC* nonmetastatic
by NGI)
3. A similar system for positive imaging mERPC, mERPC* (metastatic by NGI) for
metastatic disease; we believe these guidelines will better stratify men for future
evaluations
In M1 disease, results of conventional scans may be different than NGI based on the dynamic
and changing biology of the prostate cancer. Further head-to-head studies are warranted to
investigate the different implications for appropriate therapeutic approaches.

CONCLUSIONS
While traditional CT, MRI, and bone scans still have a role in initially diagnosing prostate
cancer, NGI modalities are more sensitive in visualizing advanced prostate cancer. These new
scans are recommended for select patients where aggressive intervention earlier may be
indicated. Currently, the 18F-fluciclovine PET scan is the NGI technique with the best
combination of availability, specificity, and sensitivity in the US. PSMA PET/CT scans show
great diagnostic potential, but likely won’t be available for widespread use in the US for several
years.
Our strongest recommendation for use of NGI is in patients with BCR prostate cancer. This is
where the data are strongest, and the likelihood of site-directed therapy is greatest for patients
interested in such strategies. This group recognizes the lack of current efficacy and safety data
however, the purpose of a consensus manuscript is to provide guidance in an area where clinical
decision-making is less than certain. Hence, we believe the greatest potential impact to alter
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therapy and improve patient outcomes with NGI are in a setting where reintroduction of local
therapy +/- systemic therapy has the greatest potential.

29

Abbreviations and Acronyms
18

F-FACBC = 18F-fluciclovine

18

F FDG = 18F-fluorodeoxyglucose

18

F-FDHT = 18F-fluoro-5alpha-dihydrotestosterone

18

F NaF = sodium fluoride

ACR = American College of Radiology
ACRIN = American College of Radiology Imaging Network
AMI = Academy of Molecular Imaging
ANDA = abbreviated new drug application
BCR = biochemically recurrent
CHAARTED = ChemoHormonal therapy versus Androgen Ablation Randomized Trial for Extensive Disease in prostate cancer
CI = confidence interval
CMS = Centers for Medicare and Medicaid Services
CPT = current procedural terminology
CT = computed tomography
ERPC = endocrine-resistant prostate cancer
FDA = Food and Drug Administration
Ga = 68Gallium
IMPACT = IMmunotherapy for Prostate AdenoCarcinoma Treatment
LATITUDE = A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus
ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
mCRPC = metastatic castration-resistant prostate cancer
mHSPC = metastatic hormone-sensitive prostate cancer
MDT = metastasis-directed therapy
MRI = magnetic resonance imaging
NDA = new drug application
NGI = next generation imaging
nmCRPC = nonmetastatic castration-resistant prostate cancer
NOPR = National Oncology PET Registry
OS = overall survival
PARP = poly-(adenosine diphosphate-ribose) polymerase
PET = positron emission tomography
PFS = progression-free survival
PROSPER = A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic
Castration-resistant Prostate Cancer
PSA = prostate-specific antigen
PSADT = prostate-specific antigen doubling time
PSMA = prostate-specific membrane antigen
RADAR = Radiographic Assessments for Detection of Advanced Recurrence
SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509
STAMPEDE = Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
STS = subsequent treatment strategy
US = United States
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